Name | Samalizumab |
---|
Description | Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1]. |
---|---|
Related Catalog | |
In Vitro | Samalizumab 被合理设计为具有 Ig G2/G4 恒定区,以最大限度地减少效应子功能并保护免疫细胞亚群。Samalizumab 是一种重组人源化抗 CD200 单抗,旨在消除效应子功能,特异性结合免疫检查点 CD200,阻断受体参与和信号传导,并拮抗 CD200 驱动的免疫抑制,从而发挥抗肿瘤作用免疫反应[1]。 |
References |
No Any Chemical & Physical Properties |